The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation

David P. Kodack, Vasileios Askoxylakis, Gino B. Ferraro, Qing Sheng, Mark Badeaux, Shom Goel, Xiaolong Qi, Ram Shankaraiah, Z. Alexander Cao, Rakesh R. Ramjiawan, Divya Bezwada, Bhushankumar Patel, Yongchul Song, Carlotta Costa, Kamila Naxerova, Christina S.F. Wong, Jonas Kloepper, Rita Das, Angela Tam, Jantima TanboonDan G. Duda, Ryan Miller, Marni B. Siegel, Carey K. Anders, Melinda Sanders, Monica V. Estrada, Robert Schlege, Carlos L. Arteaga, Elena Brachtel, Alan Huang, Dai Fukumura, Jeffrey A. Engelman, Rakesh K. Jain

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Although targeted therapies are often effective systemically, they fail to adequately control brain metastases. In preclinical models of breast cancer that faithfully recapitulate the disparate clinical responses in these microenvironments, we observed that brain metastases evade phosphatidylinositide 3-kinase (PI3K) inhibition despite drug accumulation in the brain lesions. In comparison to extracranial disease, we observed increased HER3 expression and phosphorylation in brain lesions. HER3 blockade overcame the resistance of HER2-amplified and/or PIK3CA-mutant breast cancer brain metastases to PI3K inhibitors, resulting in marked tumor growth delay and improvement in mouse survival. These data provide a mechanistic basis for therapeutic resistance in the brain microenvironment and identify translatable treatment strategies for HER2-amplified and/or PIK3CAmutant breast cancer brain metastases. 2017

Original languageEnglish (US)
JournalScience Translational Medicine
Volume9
Issue number391
DOIs
StatePublished - May 24 2017

Fingerprint

Phosphotransferases
Breast Neoplasms
Neoplasm Metastasis
Brain
Brain Neoplasms
Phosphorylation
Therapeutics
Growth
Pharmaceutical Preparations
Neoplasms

ASJC Scopus subject areas

  • Medicine(all)

Cite this

The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation. / Kodack, David P.; Askoxylakis, Vasileios; Ferraro, Gino B.; Sheng, Qing; Badeaux, Mark; Goel, Shom; Qi, Xiaolong; Shankaraiah, Ram; Cao, Z. Alexander; Ramjiawan, Rakesh R.; Bezwada, Divya; Patel, Bhushankumar; Song, Yongchul; Costa, Carlotta; Naxerova, Kamila; Wong, Christina S.F.; Kloepper, Jonas; Das, Rita; Tam, Angela; Tanboon, Jantima; Duda, Dan G.; Miller, Ryan; Siegel, Marni B.; Anders, Carey K.; Sanders, Melinda; Estrada, Monica V.; Schlege, Robert; Arteaga, Carlos L.; Brachtel, Elena; Huang, Alan; Fukumura, Dai; Engelman, Jeffrey A.; Jain, Rakesh K.

In: Science Translational Medicine, Vol. 9, No. 391, 24.05.2017.

Research output: Contribution to journalArticle

Kodack, DP, Askoxylakis, V, Ferraro, GB, Sheng, Q, Badeaux, M, Goel, S, Qi, X, Shankaraiah, R, Cao, ZA, Ramjiawan, RR, Bezwada, D, Patel, B, Song, Y, Costa, C, Naxerova, K, Wong, CSF, Kloepper, J, Das, R, Tam, A, Tanboon, J, Duda, DG, Miller, R, Siegel, MB, Anders, CK, Sanders, M, Estrada, MV, Schlege, R, Arteaga, CL, Brachtel, E, Huang, A, Fukumura, D, Engelman, JA & Jain, RK 2017, 'The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation', Science Translational Medicine, vol. 9, no. 391. https://doi.org/10.1126/scitranslmed.aal4682
Kodack, David P. ; Askoxylakis, Vasileios ; Ferraro, Gino B. ; Sheng, Qing ; Badeaux, Mark ; Goel, Shom ; Qi, Xiaolong ; Shankaraiah, Ram ; Cao, Z. Alexander ; Ramjiawan, Rakesh R. ; Bezwada, Divya ; Patel, Bhushankumar ; Song, Yongchul ; Costa, Carlotta ; Naxerova, Kamila ; Wong, Christina S.F. ; Kloepper, Jonas ; Das, Rita ; Tam, Angela ; Tanboon, Jantima ; Duda, Dan G. ; Miller, Ryan ; Siegel, Marni B. ; Anders, Carey K. ; Sanders, Melinda ; Estrada, Monica V. ; Schlege, Robert ; Arteaga, Carlos L. ; Brachtel, Elena ; Huang, Alan ; Fukumura, Dai ; Engelman, Jeffrey A. ; Jain, Rakesh K. / The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation. In: Science Translational Medicine. 2017 ; Vol. 9, No. 391.
@article{bd7dd83e4a4f49c59dd7f893319e7e15,
title = "The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation",
abstract = "Although targeted therapies are often effective systemically, they fail to adequately control brain metastases. In preclinical models of breast cancer that faithfully recapitulate the disparate clinical responses in these microenvironments, we observed that brain metastases evade phosphatidylinositide 3-kinase (PI3K) inhibition despite drug accumulation in the brain lesions. In comparison to extracranial disease, we observed increased HER3 expression and phosphorylation in brain lesions. HER3 blockade overcame the resistance of HER2-amplified and/or PIK3CA-mutant breast cancer brain metastases to PI3K inhibitors, resulting in marked tumor growth delay and improvement in mouse survival. These data provide a mechanistic basis for therapeutic resistance in the brain microenvironment and identify translatable treatment strategies for HER2-amplified and/or PIK3CAmutant breast cancer brain metastases. 2017",
author = "Kodack, {David P.} and Vasileios Askoxylakis and Ferraro, {Gino B.} and Qing Sheng and Mark Badeaux and Shom Goel and Xiaolong Qi and Ram Shankaraiah and Cao, {Z. Alexander} and Ramjiawan, {Rakesh R.} and Divya Bezwada and Bhushankumar Patel and Yongchul Song and Carlotta Costa and Kamila Naxerova and Wong, {Christina S.F.} and Jonas Kloepper and Rita Das and Angela Tam and Jantima Tanboon and Duda, {Dan G.} and Ryan Miller and Siegel, {Marni B.} and Anders, {Carey K.} and Melinda Sanders and Estrada, {Monica V.} and Robert Schlege and Arteaga, {Carlos L.} and Elena Brachtel and Alan Huang and Dai Fukumura and Engelman, {Jeffrey A.} and Jain, {Rakesh K.}",
year = "2017",
month = "5",
day = "24",
doi = "10.1126/scitranslmed.aal4682",
language = "English (US)",
volume = "9",
journal = "Science Translational Medicine",
issn = "1946-6234",
publisher = "American Association for the Advancement of Science",
number = "391",

}

TY - JOUR

T1 - The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation

AU - Kodack, David P.

AU - Askoxylakis, Vasileios

AU - Ferraro, Gino B.

AU - Sheng, Qing

AU - Badeaux, Mark

AU - Goel, Shom

AU - Qi, Xiaolong

AU - Shankaraiah, Ram

AU - Cao, Z. Alexander

AU - Ramjiawan, Rakesh R.

AU - Bezwada, Divya

AU - Patel, Bhushankumar

AU - Song, Yongchul

AU - Costa, Carlotta

AU - Naxerova, Kamila

AU - Wong, Christina S.F.

AU - Kloepper, Jonas

AU - Das, Rita

AU - Tam, Angela

AU - Tanboon, Jantima

AU - Duda, Dan G.

AU - Miller, Ryan

AU - Siegel, Marni B.

AU - Anders, Carey K.

AU - Sanders, Melinda

AU - Estrada, Monica V.

AU - Schlege, Robert

AU - Arteaga, Carlos L.

AU - Brachtel, Elena

AU - Huang, Alan

AU - Fukumura, Dai

AU - Engelman, Jeffrey A.

AU - Jain, Rakesh K.

PY - 2017/5/24

Y1 - 2017/5/24

N2 - Although targeted therapies are often effective systemically, they fail to adequately control brain metastases. In preclinical models of breast cancer that faithfully recapitulate the disparate clinical responses in these microenvironments, we observed that brain metastases evade phosphatidylinositide 3-kinase (PI3K) inhibition despite drug accumulation in the brain lesions. In comparison to extracranial disease, we observed increased HER3 expression and phosphorylation in brain lesions. HER3 blockade overcame the resistance of HER2-amplified and/or PIK3CA-mutant breast cancer brain metastases to PI3K inhibitors, resulting in marked tumor growth delay and improvement in mouse survival. These data provide a mechanistic basis for therapeutic resistance in the brain microenvironment and identify translatable treatment strategies for HER2-amplified and/or PIK3CAmutant breast cancer brain metastases. 2017

AB - Although targeted therapies are often effective systemically, they fail to adequately control brain metastases. In preclinical models of breast cancer that faithfully recapitulate the disparate clinical responses in these microenvironments, we observed that brain metastases evade phosphatidylinositide 3-kinase (PI3K) inhibition despite drug accumulation in the brain lesions. In comparison to extracranial disease, we observed increased HER3 expression and phosphorylation in brain lesions. HER3 blockade overcame the resistance of HER2-amplified and/or PIK3CA-mutant breast cancer brain metastases to PI3K inhibitors, resulting in marked tumor growth delay and improvement in mouse survival. These data provide a mechanistic basis for therapeutic resistance in the brain microenvironment and identify translatable treatment strategies for HER2-amplified and/or PIK3CAmutant breast cancer brain metastases. 2017

UR - http://www.scopus.com/inward/record.url?scp=85020010538&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020010538&partnerID=8YFLogxK

U2 - 10.1126/scitranslmed.aal4682

DO - 10.1126/scitranslmed.aal4682

M3 - Article

C2 - 28539475

AN - SCOPUS:85020010538

VL - 9

JO - Science Translational Medicine

JF - Science Translational Medicine

SN - 1946-6234

IS - 391

ER -